abrocitinib
Pre-clinicalActive 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Severe Uncontrolled Atopic Dermatitis
Conditions
Severe Uncontrolled Atopic Dermatitis
Trial Timeline
— → —
NCT ID
NCT05466578About abrocitinib
abrocitinib is a pre-clinical stage product being developed by Pfizer for Severe Uncontrolled Atopic Dermatitis. The current trial status is active. This product is registered under clinical trial identifier NCT05466578. Target conditions include Severe Uncontrolled Atopic Dermatitis.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04564755 | Pre-clinical | Completed |
| NCT05466578 | Pre-clinical | Active |
| NCT06899204 | Pre-clinical | Recruiting |
| NCT06807281 | Phase 3 | Recruiting |
| NCT06807268 | Phase 3 | Recruiting |
| NCT05721937 | Pre-clinical | Recruiting |
| NCT05689151 | Pre-clinical | Recruiting |
| NCT05391061 | Pre-clinical | Recruiting |
| NCT05038982 | Phase 2 | Completed |
Competing Products
20 competing products in Severe Uncontrolled Atopic Dermatitis